Metastatic osteosarcoma challenged by regorafenib
نویسندگان
چکیده
منابع مشابه
Metastatic giant cell osteosarcoma in a cat
A four-year-old male Persian cat was referred with three weeks history of progressive lameness due to a rigid osseous mass with 3.50×2.50×2.00 cm in dimensions in his left arm. In the histopathological evaluation of bone biopsy, two distinct populations of cells including multinucleated giant cells and oval cells which embedded in a fibro-osseous stroma and surrounded by lamellar bone trabecula...
متن کاملOrbital metastatic osteosarcoma.
A 15-year-old girl with right tibial osteosarcoma, diagnosed 22 months previously, developed right orbital and skull base metastases, with symptoms including painful protrusion of the right eyeball and severe visual impairment. She underwent embolization of the metastatic tumor, local irradiation, and chemotherapy followed by intralesional resection of the mass because extensive involvement of ...
متن کاملRegorafenib-Induced Hyperammonemic Encephalopathy in Metastatic Colon Cancer
Regorafenib, a multi-targeted tyrosine kinase inhibitor (TKI), is used in metastatic colorectal cancer (mCRC) and gastrointestinal stromal tumors (GIST) for salvageline therapy. From clinical trials, the most commonly reported adverse events of regorafenib are hand-foot skin reactions, fatigue, diarrhea and hypertension. We report two cases of hyperammonemic encephalopathy induced by regorafeni...
متن کاملGene Amplification in Metastatic Osteosarcoma
The human homologue of the murine double minute 2 gene (MDM2), a p53-binding protein which may act as a regulator of p53 protein function, has recently heen cloned. Initial studies of this gene in a variety of human tumors have shown frequent gene amplification in most types of sarcomas, including osteosarcomas. Amplification of the MIÃŒM2 gene may produce a functional inactivation of the p53 p...
متن کاملFDA approves regorafenib (Stivarga) for metastatic colorectal cancer.
“Stivarga is the latest colorectal cancer treatment to demonstrate an ability to extend patients’ lives, and is the second drug approved for patients with colorectal cancer in the past 2 months,” said Richard Pazdur, MD, director of the office of hematology and oncology products in FDA’s Center for Drug Evaluation and Research, in a press release. In August, the FDA approved aflibercept (Zaltra...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Lancet Oncology
سال: 2019
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(18)30821-0